Oral GLP-1 Competition Heats Up
Eli Lilly's Foundayo (orforglipron) has received FDA approval, officially entering the competitive obesity treatment market and intensifying its commercial battle with rival Novo Nordisk. Launched on April 6, Foundayo is a once-daily oral GLP-1 drug for weight loss and maintenance. This approval follows Novo Nordisk's earlier launch of its oral Wegovy in early 2026. Foundayo's entry sparks comparisons; both oral drugs are priced at $149 per month for the lowest self-pay dose, aiming for wide patient access. Eli Lilly's stock reacted positively, climbing over 3.74% following the announcement, while Novo Nordisk shares saw a slight dip.
Foundayo's Dosing Differentiator
Lilly is betting on Foundayo's convenience to capture market share. Unlike Novo Nordisk's oral Wegovy, which must be taken in the morning on an empty stomach with a 30-minute wait before eating or drinking, Foundayo can be taken anytime, with or without food. This flexibility addresses a key patient preference for simpler treatment regimens. Clinical trials demonstrated significant weight loss, with patients on the highest dose of Foundayo losing an average of 12.4% of their body weight over 72 weeks. While Novo Nordisk's oral Wegovy showed slightly higher average weight loss figures in trials (around 14%), the perceived convenience of Foundayo could prove a crucial factor in patient uptake.
Market Expansion and Valuation Dynamics
The GLP-1 market is booming, with projections estimating it could reach $156 billion to over $268 billion by 2030. Oral formulations are expected to capture a substantial share, potentially over one-third of this market. This expansion benefits both Lilly and Novo Nordisk, though it intensifies competition. Eli Lilly's valuation reflects its strong position, with a P/E ratio around 38.55-41.59 in March/April 2026. Novo Nordisk, despite its established presence, trades at a significantly lower P/E ratio of approximately 9.73-10.34, suggesting market pricing that reflects different growth expectations or current challenges. Analysts generally maintain a positive outlook on Eli Lilly, with average price targets around $1,177-$1,300, while sentiment on Novo Nordisk is more mixed, with a wide range of price targets from $41 to $160.
Risks and Competitive Pressures
While Foundayo's approval is a clear win, risks and challenges persist. Both Foundayo and oral Wegovy carry an FDA "boxed warning" for an increased risk of thyroid C-cell tumors, a caution based on rodent studies. However, recent analyses suggest this risk may not translate to humans for common thyroid cancers, mitigating some investor concern. Gastrointestinal side effects, such as nausea and vomiting, remain common across GLP-1 drugs, potentially impacting patient adherence. Novo Nordisk faces additional challenges, including reports that its weight-loss drugs may reduce the risk of new substance use disorders. The company is also experiencing market share erosion in both diabetes and obesity segments, alongside a failed pivotal trial for its next-generation obesity drug, CagriSema. The rise of compounded GLP-1 alternatives also poses a threat to pricing power, though regulatory crackdowns are underway. While Lilly's oral pill offers dosing convenience, Novo Nordisk's oral Wegovy benefits from a first-mover advantage and an established brand name. Long-term pricing strategies, market share dynamics, and evolving regulatory scrutiny will be critical for sustained success.
Future Outlook and Market Trajectory
The obesity and GLP-1 market is projected for substantial continued growth, driven by rising obesity and diabetes rates, expanded drug indications, and the introduction of more accessible oral therapies. Analysts forecast the GLP-1 market to reach hundreds of billions of dollars by 2030, with oral formulations playing an increasingly dominant role. Both Eli Lilly and Novo Nordisk are expected to benefit from this expansion, though their respective market positions will be continually tested by innovation, pricing pressures, and competitive dynamics. Foundayo's launch is anticipated to contribute significantly to Eli Lilly's revenue growth, reinforcing its premium valuation as it seeks to capture a larger share of this lucrative therapeutic area.